New Comprehensive Phase 3 Data Show First-in-Class TREMFYA ® (guselkumab) Provided Durable Improvements in Measures of Psoriatic Arthritis (PsA) Disease Activity Through Two Years

SPRING HOUSE, PENNSYLVANIA, November 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced comprehensive efficacy and safety data from the DISCOVER–2 trial of TREMFYA® (guselkumab) were published in Arthritis & Rheumatology, representing the final results of the first two-year clinical trial investigating a selective interleukin (IL)-23 inhibitor therapy in active psoriatic arthritis (PsA).1 Results show a majority of TREMFYA-treated biologic-naïve adult patients with active PsA achieved improvements in joint signs and symptoms (American College of Rheumatology [ACR] 20/50/70)a and complete skin clearance (Investigator’s Global Assessment [IGA] 0)b that were maintained or increased over time, suggesting continued TREMFYA treatment may lead to higher levels of symptom improvement. TREMFYA demonstrated low rates of radiographic progression,c a key indicator of structural damage, which includes erosion and joint space narrowing, and provided substantial and durable improvements across multiple additional disease domains, including achievement of minimal disease activity (MDA)d and normalized physical function (Health Assessment Questionnaire Disability Index [HAQ-DI] ≤0.5).1,2,e“These comprehensive, two-year data yield important insights into how patients with psoriatic arthritis can achieve and sustain improvements across symptoms with the ultimate goal being full remission,” said study investigator Philip Mease,f M.D., Direct...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news